Mumbai: Bangalore-based biotechnology firm, Biocon, plans to launch an oral insulin drug by early 2011 and is in talks with a few firms for licensing it, a top company official said.
“If everything goes well, we hope that the product will enter the Indian market by early 2011,” Biocon chairman and managing director Kiran Mazumdar Shaw told reporters in Mumbai.
The company hopes to sign the licensing agreement next year depending on the outcome of the final phase of trial and after securing the regulatory approval, Shaw said.
The clinical trial for the oral insulin drug — IN-105 — has now entered its third phase and is being carried out in 15 research and development centres pan-India, Shaw said.
The new oral insulin drug is a new proprietary insulin, which can be delivered at room temperature, she said.
The company is also planning to launch another drug called anti-CD6 monoclone antibody in near future to treat rheumatoid arthritis and psoriasis.
Biocon has targeted a turnover of Rs2,000 crore for FY’10 compared to Rs1,500 crore last fiscal, Shaw said.